FDA Compliance Training: Pharmacogenetic Assessment System Device Classification (21 CFR 862.3364)
Stay current with the latest FDA regulatory developments for pharmacogenetic assessment systems. This course delivers clear, actionable guidance on the implications of classifying these devices as class II with special controls under 21 CFR 862.3364. Learn the specific compliance steps for manufacturers, validation and labeling requirements, reporting obligations, and the risks of non-compliance. Equip your team to confidently meet regulatory expectations and maintain market access for innovative pharmacogenetic technologies.
In this course you will learn the following:
* Understand the FDA’s rationale for classifying pharmacogenetic assessment systems as class II devices.
* Identify the special controls and general controls required for compliance.
* Implement the necessary steps to meet labeling, validation, and reporting requirements.
* Recognize the legal and regulatory consequences of failing to comply with the final rule.
NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.